Cover Image
Market Research Report

Asia-Pacific Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026

Published by Data Bridge Market Research Private Limited Product code 836037
Published Content info 350 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia-Pacific Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026
Published: April 1, 2019 Content info: 350 Pages
Description

Asia-Pacific lung cancer therapeutics market is expected to grow at a healthy CAGR of 13.9% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (Japan, China, India, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

  • On the basis of cancer type, the non-small cell lung cancer is dominating the global lung cancer therapeutics market. Lung cancer is the second most common cancer type including small cell and non-small cell lung cancer. Amongst these 80 -85% cases are non-small cell lung cancer. This type of cancer grows and spreads more slowly than small cell lung cancer and therefore it is dominating the market.
  • On the basis of molecule type, the small molecule segment is dominating the global lung cancer therapeutics market. The small molecule better effects and progression free survival of lung cancer and these agents also inhibit the growth of the metastatic cell. Due to all these reasons they are more preferred than the other types.
  • On the drug class, the alkylating drug segment is dominating the lung cancer therapeutics market. This is the first discovered drug for the treatment of cancer. Alkylating directly damage DNA and prevents the cancer cells cell division. The alkylating agent can be used in every stage of cancer. This drug shows pre and post stage. This drug also shows reduced drug accumulation and the increased detoxification.
  • On the basis of treatment type, the chemotherapy segment is dominating the lung cancer therapeutics market. Chemotherapy is a traditional process in which drugs are used to kill or inhibit cancerous cells as it is the most accepted treatment. Whereas, targeted therapy is becoming more familiar in the lung cancer sector as these classes of drugs specifically focuses on specific genetic mutations present in the tumor cells.
  • On the basis of therapy type, single drug therapy segment is dominating the lung cancer therapeutics market. The single drug therapy is the first evolved therapy used for the treatment of lung cancer. Single drug therapy is dominating the market as it is mostly preferred for the treatment of old age population, patients with poor performance status and patients who are not able to take the combination therapy. Whereas the combination drug therapy is expected to grow in future as many combination drugs are under clinical trials and is expected to launch soon. Also, few studies have shown that combination drugs can have better results as compared to the single drug therapy which will contribute to the growth of the combination therapy in the forecast period.
  • On the basis of end user, hospitals segment is dominating the lung cancer therapeutics market. The hospital segment is dominating in the lung cancer therapeutics because hospitals provides many advantages over the other segments which includes, 24hours supportive care, immediate care for the emergency, availability of physicians, surgeons and medication.
  • On the basis of distribution channel, hospital pharmacy segment is dominating the lung cancer therapeutics market. Hospital pharmacy is dominating the global lung cancer therapeutics market as the lung cancer therapy products are prescribed based which is majorly available in hospital pharmacy.

Key Market Players:

The key market players for Asia-Pacific lung cancer therapeutics market are listed below:

  • Takeda Pharmaceutical Company Limited
  • ONO PHARMACEUTICAL CO., LTD.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly and Company.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • CELGENE CORPORATION
  • AMGEN INC.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Astellas Pharma Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 RESEARCH METHODOLOGY
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR MARKET CHALLENGE MATRIX
  • 2.9 DBMR VENDOR SHARE ANALYSIS
  • 2.10 MULTIVARIATE MODELLING
  • 2.11 PRODUCT TIME LINE
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING CASES OF LUNG CANCER
    • 3.1.2 GROWING NUMBER OF SMOKERS
    • 3.1.3 GOVERNMENT/ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS
    • 3.1.4 INCREASING AWARENESS
    • 3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES
  • 3.2 RESTRAINS
    • 3.2.1 PRICING PRESSURE
    • 3.2.2 HIGH COST
  • 3.3 OPPORTUNITIES
    • 3.3.1 APPROVALS AND PRODUCT PIPEPLINE
    • 3.3.2 HEALTH TOURISM
    • 3.3.3 NEW PRODUCT LAUNCHES

  • 3.4 CHALLENGES
    • 3.4.1 SIDE EFFECTS
    • 3.4.2 LACK OF NUMBER OF ONCOLOGISTS
    • 3.4.3 UNMET MEDICAL NEEDS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY OF LUNG CANCER

7 REGULATORY PROCEDURE

8 PIPELINE DRUGS

9 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-SMALL CELL LUNG CANCER
    • 9.2.1 SQUAMOUS CELL CARCINOMA
    • 9.2.2 PULMONARY ADENOCARCINOMA
    • 9.2.3 ADENOSQUAMOUS CARCINOMA (ASC)
    • 9.2.4 LARGE CELL CARCINOMA
    • 9.2.5 SARCOMATOID CARCINOMA
    • 9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER
    • 9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA
      • 9.2.7.1 ADENOID CYSTIC CARCINOMA
      • 9.2.7.2 MUCOEPIDERMOID CARCINOMA
      • 9.2.7.3 ACINIC CELL CARCINOMA
      • 9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA
      • 9.2.7.5 GRANULAR CELL LUNG TUMORS
  • 9.3 METASTATIC LUNG CANCER
  • 9.4 MESOTHELIOMA
  • 9.5 CHEST WALL TUMORS
    • 9.5.1 PRIMARY TUMORS
    • 9.5.2 METASTATIC TUMORS
    • 9.5.3 SARCOMAS
  • 9.6 PULMONARY NEUROENDOCRINE TUMORS
    • 9.6.1 CARCINOID TUMORS
      • 9.6.1.1 TYPICAL CARCINOID TUMORS
      • 9.6.1.2 ATYPICAL CARCINOID TUMORS
    • 9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA

    • 9.6.3 SMALL-CELL LUNG CANCER
      • 9.6.3.1 SMALL CELL CARCINOMA
      • 9.6.3.2 COMBINED SMALL CELL CARCINOMA
  • 9.7 MEDIASTINAL TUMORS
    • 9.7.1 GERM CELL TUMORS
    • 9.7.2 LYMPHOMAS
    • 9.7.3 THYMOMAS

10 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE

  • 10.1 OVERVIEW
  • 10.2 SMALL MOLECULE
  • 10.3 BILOGICS

11 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS

  • 11.1 OVERVIEW
  • 11.2 ALKYLATING AGENTS
  • 11.3 ANTIMETABOLITES
  • 11.4 MITOTIC INHIBITORS
  • 11.5 MULTIKINASE INHIBITORS
  • 11.6 EGFR INHIBITORS
  • 11.7 OTHERS

12 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE

  • 12.1 OVERVIEW
  • 12.2 RADIATION THERAPY
    • 12.2.1 EXTERNAL BEAM
    • 12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY)
    • 12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
    • 12.2.4 STEREOTACTIC RADIOSURGERY (SRS)
  • 12.3 CHEMOTHERAPY
    • 12.3.1 CISPLATIN
    • 12.3.2 PACLITAXEL (TAXOL)
    • 12.3.3 VINORELBINE (NAVELBINE)
    • 12.3.4 DOCETAXEL (TAXOTERE)
    • 12.3.5 ALIMTA
    • 12.3.6 GEMCITABINE (GEMZAR)
    • 12.3.7 DURVALUMAB (IMFINZI)
    • 12.3.8 OTHERS

  • 12.4 TARGETED THERAPY
    • 12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS
    • 12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
    • 12.4.3 ANTI-ANGIOGENESIS THERAPY
    • 12.4.4 MONOCLONAL ANTIBODIES
    • 12.4.5 OTHERS
  • 12.5 IMMUNOTHERAPY
    • 12.5.1 ATEZOLIZUMAB (TECENTRIQ)
    • 12.5.2 DURVALUMAB (IMFINZI)
    • 12.5.3 NIVOLUMAB (OPDIVO)
    • 12.5.4 PEMBROLIZUMAB (KEYTRUDA)
  • 12.6 OTHERS

13 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE

  • 13.1 OVERVIEW
  • 13.2 SINGLE DRUG THERAPY
  • 13.3 COMBINATION THERAPY

14 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 SPECIALTY CLINICS
  • 14.4 HOMECARE
  • 14.5 OTHERS

15 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE
  • 15.5 OTHERS

16 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

  • 16.1 ASIA-PACIFIC
    • 16.1.1 JAPAN
    • 16.1.2 CHINA
    • 16.1.3 INDIA
    • 16.1.4 AUSTRALIA
    • 16.1.5 SOUTH KOREA
    • 16.1.6 INDONESIA
    • 16.1.7 THAILAND
    • 16.1.8 MALAYSIA
    • 16.1.9 SINGAPORE
    • 16.1.10 PHILIPPINES
    • 16.1.11 REST OF ASIA-PACIFIC

17 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 COMPANY PROFILES

  • 18.1 F. HOFFMANN-LA ROCHE LTD
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 GEOGRAPHICAL PRESENCE
    • 18.1.4 COMPANY SHARE ANALYSIS
    • 18.1.5 PRODUCT PORTFOLIO
    • 18.1.6 RECENT DEVELOPMENTS
  • 18.2 MERCK & CO., INC.
    • 18.2.1 COMPANY OVERVIEW
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 GEOGRAPHICAL PRESENCE
    • 18.2.4 COMPANY SHARE ANALYSIS
    • 18.2.5 PRODUCT PORTFOLIO
    • 18.2.6 RECENT DEVELOPMENTS
  • 18.3 BRISTOL-MYERS SQUIBB COMPANY
    • 18.3.1 COMPANY OVERVIEW
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 GEOGRAPHICAL PRESENCE
    • 18.3.4 COMPANY SHARE ANALYSIS
    • 18.3.5 PRODUCT PORTFOLIO
    • 18.3.6 RECENT DEVELOPMENTS
  • 18.4 ASTRAZENECA
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 GEOGRAPHICAL PRESENCE
    • 18.4.4 COMPANY SHARE ANALYSIS
    • 18.4.5 PRODUCT PORTFOLIO
    • 18.4.6 RECENT DEVELOPMENTS

  • 18.5 ELI LILLY AND COMPANY
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 GEOGRAPHICAL PRESENCE
    • 18.5.4 COMPANY SHARE ANALYSIS
    • 18.5.5 PRODUCT PORTFOLIO
    • 18.5.6 RECENT DEVELOPMENTS
  • 18.6 ALLERGAN
    • 18.6.1 COMPANY OVERVIEW
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 GEOGRAPHICAL PRESENCE
    • 18.6.4 PRODUCT PORTFOLIO
    • 18.6.5 RECENT DEVELOPMENTS
  • 18.7 AMGEN INC.
    • 18.7.1 COMPANY OVERVIEW
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 GEOGRAPHICAL PRESENCE
    • 18.7.4 PRODUCT PORTFOLIO
    • 18.7.5 RECENT DEVELOPMENTS
  • 18.8 ASTELLAS PHARMA INC.
    • 18.8.1 COMPANY OVERVIEW
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 GEOGRAPHICAL PRESENCE
    • 18.8.4 PRODUCT PORTFOLIO
    • 18.8.5 RECENT DEVELOPMENTS
  • 18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 18.9.1 COMPANY OVERVIEW
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 GEOGRAPHICAL PRESENCE
    • 18.9.4 PRODUCT PORTFOLIO
    • 18.9.5 RECENT DEVELOPMENTS
  • 18.10 CELGENE CORPORATION
    • 18.10.1 COMPANY OVERVIEW
    • 18.10.2 REVENUE ANALYSIS
    • 18.10.3 GEOGRAPHICAL PRESENCE
    • 18.10.4 PRODUCT PORTFOLIO
    • 18.10.5 RECENT DEVELOPMENTS

  • 18.11 DR. REDDY'S LABORATORIES LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 GEOGRAPHICAL PRESENCE
    • 18.11.4 PRODUCT PORTFOLIO
    • 18.11.5 RECENT DEVELOPMENTS
  • 18.12 GLAXOSMITHKLINE PLC.
    • 18.12.1 COMPANY OVERVIEW
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 GEOGRAPHICAL PRESENCE
    • 18.12.4 PRODUCT PORTFOLIO
    • 18.12.5 RECENT DEVELOPMENTS
  • 18.13 JOHNSON & JOHNSON SERVICES, INC.
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 GEOGRAPHICAL PRESENCE
    • 18.13.4 PRODUCT PORTFOLIO
    • 18.13.5 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 GEOGRAPHICAL PRESENCE
    • 18.14.4 PRODUCT PORTFOLIO
    • 18.14.5 RECENT DEVELOPMENT
  • 18.15 ONO PHARMACEUTICAL CO., LTD.
    • 18.15.1 COMPANY OVERVIEW
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 GEOGRAPHICAL PRESENCE
    • 18.15.4 PRODUCT PORTFOLIO
    • 18.15.5 RECENT DEVELOPMENTS
  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 RECENT FINANCIALS
    • 18.16.3 GEOGRAPHICAL PRESENCE
    • 18.16.4 PRODUCT PORTFOLIO
    • 18.16.5 RECENT DEVELOPMENTS

  • 18.17 SANOFI
    • 18.17.1 COMPANY OVERVIEW
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 GEOGRAPHICAL PRESENCE
    • 18.17.4 PRODUCT PORTFOLIO
    • 18.17.5 RECENT DEVELOPMENTS
  • 18.18 SUMITOMO DAINIPPON PHARMA CO., LTD.
    • 18.18.1 COMPANY OVERVIEW
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 GEOGRAPHICAL PRESENCE
    • 18.18.4 PRODUCT PORTFOLIO
    • 18.18.5 RECENT DEVELOPMENTS
  • 18.19 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 GEOGRAPHICAL PRESENCE
    • 18.19.4 PRODUCT PORTFOLIO
    • 18.19.5 RECENT DEVELOPMENTS
  • 18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.20.1 COMPANY OVERVIEW
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 GEOGRAPHICAL PRESENCE
    • 18.20.4 PRODUCT PORTFOLIO
    • 18.20.5 RECENT DEVELOPMENTS
  • 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 18.21.1 COMPANY OVERVIEW
    • 18.21.2 REVENUE ANALYSIS
    • 18.21.3 GEOGRAPHICAL PRESENCE
    • 18.21.4 PRODUCT PORTFOLIO
    • 18.21.5 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

LIST OF TABLES

  • TABLE 1 PREVALENCE OF SUBTYPES OF LUNG CARCINOMA IN SMOKERS AND NEVER-SMOKERS
  • TABLE 2 COST OF TARGETED THERAPIES FOR THE TREATMENT OF NSCLC (2018)
  • TABLE 3 COST OF IMMUNOTHERAPIES FOR THE TREATMENT OF NSCLC (2018)

TABLE 4 SOME OF THE PIPELINE LUNG CANCER DRUGS ARE MENTIONED IN THE BELOW TABLE:

  • TABLE 5 AVERAGE COST OF LUNG CANCER TREATMENT (2018)
  • TABLE 6 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 9 ASIA-PACIFIC SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 10 ASIA-PACIFIC METASTATIC LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 11 ASIA-PACIFIC MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 12 ASIA-PACIFIC CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 13 ASIA-PACIFIC CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 14 ASIA-PACIFIC PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 15 ASIA-PACIFIC PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 16 ASIA-PACIFIC CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 17 ASIA-PACIFIC SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 18 ASIA-PACIFIC MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 19 ASIA-PACIFIC MESOTHELIOMA IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 21 ASIA-PACIFIC SMALL MOLECULE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 22 ASIA-PACIFIC BIOLOGICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 23 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 24 ASIA-PACIFIC ALKYLATING AGENTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 25 ASIA-PACIFIC ANTIMETABOLITES IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 26 ASIA-PACIFIC MITOTIC INHIBITORS PRODUCTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 27 ASIA-PACIFIC MULTIKINASE INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 28 ASIA-PACIFIC EGFR INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 29 ASIA-PACIFIC OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 30 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 31 ASIA-PACIFIC RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 32 ASIA-PACIFIC RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 33 ASIA-PACIFIC CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 34 ASIA-PACIFIC CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 35 ASIA-PACIFIC TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 36 ASIA-PACIFIC TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 37 ASIA-PACIFIC IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 38 ASIA-PACIFIC IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 39 ASIA-PACIFIC OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 40 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 41 ASIA-PACIFIC SINGLE DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 42 ASIA-PACIFIC COMBINATION DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 43 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 44 ASIA-PACIFIC HOSPITALS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 45 ASIA-PACIFIC SPECIALTY CLINICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 46 ASIA-PACIFIC HOMECARE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 47 ASIA-PACIFIC OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 48 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 49 ASIA-PACIFIC HOSPITAL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 50 ASIA-PACIFIC RETAIL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 51 ASIA-PACIFIC ONLINE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 52 ASIA-PACIFIC OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 53 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 54 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 55 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 56 ASIA-PACIFIC SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 57 ASIA-PACIFIC CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 58 ASIA-PACIFIC PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 59 ASIA-PACIFIC SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 60 ASIA-PACIFIC CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 61 ASIA-PACIFIC MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 62 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 63 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 64 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 65 ASIA-PACIFIC CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 66 ASIA-PACIFIC RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 67 ASIA-PACIFIC TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 68 ASIA-PACIFIC IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 69 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 70 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 71 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 72 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 73 JAPAN NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 74 JAPAN SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 75 JAPAN CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 76 JAPAN PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 77 JAPAN SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 78 JAPAN CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 79 JAPAN MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 80 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 81 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 82 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 83 JAPAN CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 84 JAPAN RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 85 JAPAN TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 86 JAPAN IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 87 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 88 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 89 JAPAN LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 90 CHINA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 91 CHINA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 92 CHINA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 93 CHINA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)T
  • TABLE 94 CHINA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 95 CHINA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 96 CHINA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 97 CHINA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 98 CHINA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 99 CHINA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 100 CHINA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 101 CHINA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 102 CHINA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 103 CHINA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 104 CHINA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 105 CHINA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 106 CHINA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 107 CHINA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 108 INDIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 109 INDIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 110 INDIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 111 INDIA CHEST WALL TOMOURS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 112 INDIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 113 INDIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 114 INDIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 115 INDIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 116 INDIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 117 INDIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 118 INDIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 119 INDIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 120 INDIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 121 INDIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 122 INDIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 123 INDIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 124 INDIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 125 INDIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 126 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 127 AUSTRALIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 128 AUSTRALIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 129 AUSTRALIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 130 AUSTRALIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 131 AUSTRALIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 132 AUSTRALIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 133 AUSTRALIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 134 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 135 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 136 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 137 AUSTRALIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 138 AUSTRALIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 139 AUSTRALIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 140 AUSTRALIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 141 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 142 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 143 AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 144 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 145 SOUTH KOREA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 146 SOUTH KOREA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 147 SOUTH KOREA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 148 SOUTH KOREA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 149 SOUTH KOREA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 150 SOUTH KOREA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 151 SOUTH KOREA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 152 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 153 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 154 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 155 SOUTH KOREA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 156 SOUTH KOREA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 157 SOUTH KOREA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 158 SOUTH KOREA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 159 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 160 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 161 SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 162 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 163 INDONESIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 164 INDONESIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 165 INDONESIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 166 INDONESIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 167 INDONESIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 168 INDONESIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 169 INDONESIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 170 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 171 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 172 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 173 INDONESIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 174 INDONESIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 175 INDONESIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 176 INDONESIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 177 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 178 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 179 INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 180 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 181 THAILAND NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 182 THAILAND SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 183 THAILAND CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 184 THAILAND PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 185 THAILAND SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 186 THAILAND CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 187 THAILAND MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 188 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 189 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 190 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 191 THAILAND CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 192 THAILAND RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 193 THAILAND TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 194 THAILAND IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 195 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 196 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 197 THAILAND LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 198 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 199 MALAYSIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 200 MALAYSIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 201 MALAYSIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 202 MALAYSIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 203 MALAYSIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 204 MALAYSIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 205 MALAYSIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 206 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 207 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 208 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 209 MALAYSIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 210 MALAYSIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 211 MALAYSIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 212 MALAYSIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 213 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 214 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 215 MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 216 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 217 SINGAPORE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 218 SINGAPORE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 219 SINGAPORE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 220 SINGAPORE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 221 SINGAPORE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 222 SINGAPORE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 223 SINGAPORE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 224 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 225 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 226 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 227 SINGAPORE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 228 SINGAPORE RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 229 SINGAPORE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 230 SINGAPORE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 231 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 232 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 233 SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 234 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 235 PHILIPPINES NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 236 PHILIPPINES SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 237 PHILIPPINES CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 238 PHILIPPINES PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 239 PHILIPPINES SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 240 PHILIPPINES CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 241 PHILIPPINES MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 242 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 243 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 244 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 245 PHILIPPINES CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 246 PHILIPPINES RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 247 PHILIPPINES TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 248 PHILIPPINES IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 249 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 250 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 251 PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 252 REST OF ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 2 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: DATA VALIDATION MODEL
  • FIGURE 3 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: DROC ANALYSIS
  • FIGURE 4 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: THE MARKET CHALLENGE MATRIX
  • FIGURE 9 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET
  • FIGURE 11 COUNTRY WISE LUNG CANCER RATES IN 2018
  • FIGURE 12 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 13 INCREASING CASES OF LUNG CANCER, GROWING NUMBER OF SMOKERS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026
  • FIGURE 14 NON-SMALL CELL LUNG CANCER IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET IN 2019 & 2026
  • FIGURE 15 ASIA-PACIFIC IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 16 WORLDWIDE LUNG CANCER INCIDENCE (2018)
  • FIGURE 17 WORLDWIDE PREVALENCE OF LUNG CANCER FOR LAST 5 YEARS
  • FIGURE 18 WORLDWIDE MORTALITY RATE OF LUNG CANCER (2018)
  • FIGURE 19 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE, 2018
  • FIGURE 20 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY MOLECULE TYPE, 2018
  • FIGURE 21 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY DRUG CLASS, 2018
  • FIGURE 22 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE, 2018
  • FIGURE 23 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY THERAPY TYPE, 2018
  • FIGURE 24 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY END USER, 2018
  • FIGURE 25 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2018
  • FIGURE 26 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 27 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 28 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 29 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 30 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 31 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)
Back to Top